Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0684
D

Failure to Monitor for Side Effects After Medication Error with Psychotropic Drug

Walnut Creek, California Survey Completed on 06-05-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

A resident with a history of hip fracture and depression, and moderate cognitive impairment, was admitted to the facility and subsequently administered divalproex sodium (Depakote), a mood stabilizing medication, in error. The resident's Minimum Data Set indicated no symptoms of mood disturbances or behavioral issues that would warrant the use of this medication. Despite this, the medication was ordered and administered for mood instability, and there was no evidence of monitoring for side effects or effectiveness during the period it was given. Interviews with facility staff, including the Facility Medical Practitioner, DON, and Facility Pharmacy Consultant, confirmed that the resident was not monitored for behavioral changes or adverse effects associated with divalproex sodium. The facility's own policies required monitoring for side effects and effectiveness of psychotropic medications, as well as monitoring after medication errors. Documentation review showed that the pharmacy consultant recommended adding monitoring, but this was not implemented, and no monitoring was documented on the Medication Administration Record.

An unhandled error has occurred. Reload 🗙